Invests in
Sectors:
Locations:
Min Investment:
$10,000,000.00Max Investment:
$50,000,000.00Target Investment:
$25,000,000.00
Skills
Education
- DU
Lists including Joseph
Investments
Work Experience
2025
Board Member
2025
Medical device manufacturer with a novel beta-emitting radiotherapeutic product for the treatment of liver cancer
2024
Board Member
2024
Clinical stage biotech company focused on renal disease
2024
Managing Partner
2024
Co-head of JP Morgan’s new growth investing effort in healthcare.
2021
Board Member
2021
Led $50 million growth equity investment into a founder-controlled neurovascular-focused medical device company. Revenue grew over 10x in 1st four years post investment. Employees grew from less than 100 to over 250 in the same period.
2021 - 2025
Board Member
2021 - 2025
Led minority equity investment in founder controlled business focused on infection prevention and staff safety
Interim Chief Executive Officer
2023 - 2024
Recapitalized portfolio company focused on infection prevention and surgical staff safety solutions.
2017 - 2024
Managing Director
2017 - 2024
Leading healthcare-focused private capital firm with headquarters in Palo Alto, CA and offices in Shanghai and Beijing, China. Founded in 1996 with over US$6.5 Billion in assets under management. The firm invests across a wide range of sub segments of healthcare including but not limited to specialty pharmaceuticals, biotech, medical devices and services. Focus on commercial stage growth equity and controlling stake private equity investments. Source deals, negotiate and structure transactions and take active board roles on behalf of the firm.
2021 - 2024
Board Member
2021 - 2024
Interim Chief Executive Officer
2022 - 2022
Moved from board of directors to interim CEO role to oversee the transition from a founder run business in the tech-enabled digital pathology lab space. Managed the company, hired a recruiter and brought on an outside CEO and transitioned back to a board position.
2021 - 2024
Board Observer
2021 - 2024
Medical device manufacturer with an innovative robotic solution for dental implant procedures.
2021 - 2024
Board Member
2021 - 2024
Highly profitable pharma services company with a specialization in solving solubility issues for pharma and biotech customers.
2015 - 2024
Co-Founder/Angel Investor
2015 - 2024
Revenue stage, FDA-approved gynecology-focused medical device for minimally invasive removal of uterine polyps. Designed for both office-based and OR-based surgery with no capital equipment investment needed.